NYT article considers Bristol-Myers strategy

The Bristol-Myers Squibb's "String of Pearls" initiative to buy small biotech companies, as well as the rights to market or develop drugs from other companies, might not be the best strategy for the company, according to an article in today's New York Times.

In fact, the company's earnings report indicates that its specialization on drugs for Alzheimer disease, cancer and hepatitis C might not be enough to help it overcome lost revenues when some major drugs go off patent over the next few years.

Drugs like Abilify, Avapro and Plavix have been bringing Bristol-Myers big bucks, but the company might just be suited for a merger or takeover in the current climate. 

Still, reported earnings of $1.2 billion were respectable, and ahead of forecasts, for now at least.

- see the New York Times story

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.